The recent surge in capital into boutique pharmaceutical companies, particularly those focusing on groundbreaking therapies and challenging drug development programs, has fueled what some are calling "High Roller Pharma." While the possibility for blockbuster treatments and significant returns is clear, the connected risks are also significant. … Read More